Vivanza Biosciences Ltd (VIVANZA) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Vivanza Biosciences Ltd ₹1.53, price ₹1.70, upside -10.0%, quality 52 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.
How to read this chart
60‑month range ₹1.25 – ₹21.00 · fair‑value band ₹1.10 – ₹1.93 · the ₹1.70 price screens above the ₹1.53 fair value. Dashed = 300-day average. As of Oct 3, 2026.
Follow Vivanza Biosciences in your weekly email
Every Wednesday you see whether Vivanza Biosciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Vivanza Biosciences Limited engages in the research and development, manufacturing, and the distribution of pharmaceutical products in India. It offers latex surgical and examination, and latex free gloves, as well as other surgical products. The company was incorporated in 1982 and is based in Ahmedabad, India.
Stock analysis
Vivanza Biosciences Ltd (VIVANZA) currently trades at ₹1.70, while our model-based Fair Value estimate is ₹1.53, 10.0% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹4.58 per share, and 10 of the 15 models we run sit above the ₹1.70 price.
Bear case: the Asset-Based group reads lowest at ₹0.7300, and 5 of the 15 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹1.10 (bear) to ₹1.93 (bull), the price of ₹1.70 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 52/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Vivanza Biosciences Ltd reported revenue of ₹1.2B in FY2025 versus ₹104M in FY2021, a compound +82.7%/yr. Reported net income was ₹3.9M in FY2025, compounding +4.3%/yr from FY2021.
Key figures
Market cap ₹68.0M (≈ $706K) · P/E ratio 14.2 · P/S ratio 0.05 · EPS (TTM) ₹0.1200 · Net margin 0.3% · Return on equity 9.5% · Return on assets (EBIT) 1.7% · Operating margin 3.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 35% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −10%, VIVANZA screens cheaper than that median.
Fair Value models
Bear ₹1.10Fair Value ₹1.53Bull ₹1.93
Price ₹1.70 · Upside -10.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (₹0.0911 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+86.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+63.6%
Start year 2020 (pandemic)
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+47.7%
’16
’17
’18
’19
’20
’21
’22
’23
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+14.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+14.1%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.1% → 1%
Compare Vivanza Biosciences Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 602 stocks
Beats the industry median on 7/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score52 · Below median
Fair Value upside−10.0% · Above median
Profitability
Return on equity (TTM)9.5% · Above median
Return on assets2.7% · Below median
Net margin (TTM)0.4% · Below median
Operating margin (TTM)3.0% · Below median
Growth and dividend
Revenue growth7.9% · Above median
Balance sheet
Debt / equity0.20× · Above median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Vivanza Biosciences Ltd (VIVANZA) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of ₹1.53 versus a price of ₹1.70, about −10% upside (overvalued).
What is the fair value of VIVANZA?
Our model-based fair value for Vivanza Biosciences Ltd is ₹1.53 (as of Oct 3, 2026), built from audited fundamentals. The current price: ₹1.70.
What is the quality score of VIVANZA?
Vivanza Biosciences Ltd has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vivanza Biosciences Ltd (VIVANZA)?
Our model-based price target is the fair value of ₹1.53 (as of Oct 3, 2026) from 15 valuation models. Cautious scenario ₹1.10, optimistic scenario ₹1.93. It is a calculation from audited fundamentals, not an analyst target.
What is the Vivanza Biosciences Ltd stock forecast for 2026?
Our models put fair value at ₹1.53, about −10% upside versus a price of ₹1.70 (overvalued). Cautious scenario ₹1.10, optimistic scenario ₹1.93. The calculation is refreshed regularly with new filings.
What is the revenue of Vivanza Biosciences Ltd (VIVANZA)?
Vivanza Biosciences Ltd reported trailing-twelve-month revenue of about ₹1.2B (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Vivanza Biosciences Ltd (VIVANZA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vivanza Biosciences Ltd it is ₹1.53 per share (as of Oct 3, 2026), against a price of ₹1.70. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Vivanza Biosciences Ltd stock overvalued or undervalued in 2026?
As of Oct 3, 2026, VIVANZA trades above its calculated fair value: price ₹1.70, fair value ₹1.53, a gap of about −10% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VIVANZA?
No. The price is what the market pays today (₹1.70); the fair value is what the company's own numbers justify (₹1.53). For Vivanza Biosciences Ltd the two are ₹0.1700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vivanza Biosciences Ltd worth?
The market values Vivanza Biosciences Ltd at about ₹68.0M (market capitalisation, as of Oct 3, 2026). Per share that is ₹1.70; our models calculate a fair value of ₹1.53 per share.
What do the bullish and bearish scenarios say about VIVANZA?
Our models span a range for Vivanza Biosciences Ltd: cautious scenario ₹1.10, base ₹1.53, optimistic ₹1.93 per share (as of Oct 3, 2026, price ₹1.70). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of VIVANZA?
Vivanza Biosciences Ltd trades at a price-to-earnings ratio of 14.2 (as of Oct 3, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1.53 is built from several models across several years. Other multiples: P/B 1.6, P/S 0.1, EV/EBITDA 7.8.
How solid is the balance sheet of Vivanza Biosciences Ltd (VIVANZA)?
Balance-sheet figures for Vivanza Biosciences Ltd (as of Oct 3, 2026): return on equity 9.5%, debt of 0.20 per unit of equity. They feed the Quality Score of 52/100, which measures business quality independently of the share price.
How far is VIVANZA from its 52-week high?
Vivanza Biosciences Ltd trades at ₹1.70, about 35% below its 52-week high of ₹2.61 and at the low of ₹1.70 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1.53 is for.
Which stocks are comparable to Vivanza Biosciences Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vivanza Biosciences Ltd stock attractive at the current price?
The data as of Oct 3, 2026: price ₹1.70, calculated fair value ₹1.53 (−10%), Quality Score 52/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of VIVANZA calculated?
We run Vivanza Biosciences Ltd through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹1.53, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Vivanza Biosciences Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vivanza Biosciences Ltd (VIVANZA)?
The closing price on Oct 1, 2026 was ₹1.70. Our model-based fair value is ₹1.53, about −10% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vivanza Biosciences Ltd right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Vivanza Biosciences Ltd
How large is the market capitalisation of Vivanza Biosciences Ltd (VIVANZA)?
The market capitalisation of Vivanza Biosciences Ltd is ₹68.0M (≈ $706K). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vivanza Biosciences Ltd (VIVANZA)?
The price-to-sales ratio of Vivanza Biosciences Ltd is 0.05 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vivanza Biosciences Ltd (VIVANZA)?
Earnings per share at Vivanza Biosciences Ltd are ₹0.1200 (price ÷ EPS = P/E 14.2). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vivanza Biosciences Ltd (VIVANZA)?
The net margin of Vivanza Biosciences Ltd is 0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vivanza Biosciences Ltd (VIVANZA)?
The return on equity (ROE) of Vivanza Biosciences Ltd is 9.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vivanza Biosciences Ltd (VIVANZA)?
On an EBIT basis the return on assets of Vivanza Biosciences Ltd is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vivanza Biosciences Ltd (VIVANZA)?
The operating margin of Vivanza Biosciences Ltd is 3.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vivanza Biosciences Ltd (VIVANZA)?
Revenue at Vivanza Biosciences Ltd is growing +7.9% versus a year earlier (3y avg +86.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vivanza Biosciences Ltd (VIVANZA)?
Earnings per share at Vivanza Biosciences Ltd are growing +100% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vivanza Biosciences Ltd (VIVANZA) generate?
The free cash flow of Vivanza Biosciences Ltd is −₹27.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Vivanza Biosciences Ltd (VIVANZA) carry?
The net debt of Vivanza Biosciences Ltd is ₹101M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Vivanza Biosciences Ltd in the live analysis
One click puts Vivanza Biosciences Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
